Objective: The aim of this study was to investigate the immunohistochemical stain profiling of adipocytic tumors. Methods: From our archive files between the years of 2012-2018, excised, formalin-fixed and paraffin-embedded adipocytic tumors were retrospectively screened and 61 subjects were selected. The gender, age, tumor location and tumor diameter were evaluated. The cases were investigated in terms of p16, CD34, MDM2 expression and clinicopathological information. Results: Of the 61 patients included in the study, we found that 2 had hibernoma, 4 had lipoblastoma, 14 had spindle cell lipoma (SCL), 10 had lipoma, 20 had atypical lipomatous tumor/well differentiated liposarcoma (ALT/WDL), and 11 had dedifferentiated liposarcoma (DDL). In terms of diameter, ALT/WDL and DDL were significantly different from the others (p=0.001, p=0.001, respectively). There was a significant difference between the groups according to the location (p=0.001). 35% (7/20) of ALT/WDLs were in the lower extremities (thighs) and 35% (7/20) were located in the retroperitoneal region. 70% of DDLs (7/11) were located in the retroperitoneum. When CD34 expression was evaluated among the groups, a significant difference was observed (p=0.001). CD34 was positive in 92.9% of SCL cases. p16 immunoreactivity was significantly different between the groups (p=0.001). p16 expression was observed in 50.5% of ALT / WDL cases and 79% of DDL cases. Conclusion: p16 and CD34 expression are valuable in the differential diagnosis of lipomatous tumors when radiological and clinical considerations do not help to differential diagnosis of adipocytic tumors.
Yuceturk G, Sabah D, Kececi B, Kara AD, Yalcinkaya S. Prevalence of bone and soft tissue tumors. Acta Orthop Traumatol Turc 2011; 45: 135-43. [CrossRef]
T hway K, Flora R, Shah C, Olmos D, Fisher C. Diagnostic utility of p16, CDK4, and MDM2 as an immunohistochemical panel in distinguishing well-differentiated and dedifferentiated liposarcomas from other adipocytic tumors. Am J Surg Pathol 2012; 36: 462-9. [CrossRef]
Vinay Kumar, Abul Abbas JA. Robbins basic pathology. 9th Edition. Philadelphia: Elsevier Inc.; 2014; 791-5.
Gonzalez RS, Mcclain CM, Chamberlain BK, Coffin CM, Cates JM. Cyclin-dependent kinase inhibitor 2A (p16) distinguishes well-differentiated liposarcoma from lipoma. Histopathology 2013; 62: 110911. [CrossRef]
Franz M. Enzınger DAH. Spindle cell lipoma. Cancer 1975; 36: 18529.
Furlong M a, Fanburg-Smith JC, Miettinen M. The morphologic spectrum of hibernoma: A clinicopathologic study of 170 cases. Am J Surg Pathol 2001; 25: 809-14. [CrossRef]
Cappellesso R, d’Amore ES, Dall’Igna P, et al. Immunohistochemical expression of p16 in lipoblastomas. Hum Pathol 2016; 47: 64-9. [CrossRef]
Coran A, Ortolan P, Attar S, et al. Magnetic resonance imaging assessment of lipomatous soft-tissue tumors. In Vivo 2017; 31: 387-95. [CrossRef]
Sirvent N, Coindre JM, Maire G, Hostein I, Keslair F, Guillou L. Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: Utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR. Am J Surg Pathol 2007; 31: 1476-89. [CrossRef]
10. Dabak N, Cirakli A, Gulman B, Selcuk MB, Baris S. Distribution and evaluation of bone and soft tissue tumors in the middle Black Sea Region. Acta Orthop Traumatol Turc 2014; 48: 17-24. [CrossRef]
11. Tuna B, Lebe B, Sis B, Yorukoglu K, Kargi A. Mdm2 gene expression in adipose-tissue tumors: Association with tumor progression in liposarcomas. Aegean Pathol J 2004; 1: 15-22.
12. Binh MB, Garau XS, Guillou L, Aurias A, Coindre JM. Reproducibility of MDM2 and CDK4 staining in soft tissue tumors. Am J Clin Pathol 2006; 125: 693-7. [CrossRef]
13. Thway K, Jones RL, Noujaim J, Zaidi S, Miah AB, Fisher C. Dedifferentiated liposarcoma: Updates on morphology, genetics, and therapeutic strategies. Adv Anat Pathol 2016; 23: 30-40. [CrossRef]
14. He M, Aisner S, Benevenia J, Patterson F, Aviv H, Hameed M. p16 immunohistochemistry as an alternative marker to distinguish atypical lipomatous tumor. Appl Immunohistochem Mol Morphol 2009; 17: 51-6. [CrossRef]
15. Knosel T, Altendorf-Hofmann A, Lindner L, et al. Loss of p16 ( INK4a ) is associated with reduced patient survival in soft tissue tumours, and indicates a senescence barrier. J Clin Pathol 2014; 16: 1-7. [CrossRef]
16. Rydholm A, Berg NO. Size, site and clinical incidence of lipoma: Factors in the differential diagnosis of lipoma and sarcoma. Acta Orthop Scand 1983; 54: 929-34. [CrossRef]
17. Chhabra A, Soldatos T. Soft-tissue lesions: When can we exclude sarcoma? Am J Roentgenol 2012; 199: 1345-57. [CrossRef]
18. Kransdorf MJ, Murphey MD. Radiologic evaluation of soft-tissue masses: A current perspective. AJR Am J Roentgenol 2000; 175: 57587. [CrossRef]
19. Thompson LDR. Spindle-cell lipoma. Ear, Nose Throat J 2009; 88: 7. [CrossRef]
20. Errani C, Cocchi S, Ali N, et al. Recurrence after marginal excision for atypical lipomatous tumors versus lipomas of the extremities. Orthopedics 2016; 39: e610-4. [CrossRef]
21. Rozental TD, Khoury LD, Donthineni-Rao R, Lackman RD. Atypical lipomatous masses of the extremities. Clin Orthop Relat Res 2002; 398: 203-11. [CrossRef]